secwatch.observer — SEC 8-K summary
======================================

Issuer:     PHIBRO ANIMAL HEALTH CORP (PAHC)
CIK:        0001069899
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001104659-25-122556
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Phibro Animal Health Announces CEO Transition: Jack Bendheim to Executive Chairman, Dani Bendheim to CEO
--------------------------------------------------------------------------------

- Jack C. Bendheim will resign as CEO and President effective July 1, 2026, and assume the new role of Executive Chairman.
- Daniel (Dani) Bendheim, age 53, current EVP Corporate Strategy, will become CEO and President on July 1, 2026.
- Dani Bendheim has been with Phibro since 1997 and served as VP Business Development, President Performance Products, and EVP Corporate Strategy.
- Jack Bendheim, son of founder, will continue as Chairman of the Board; the Board unanimously supports the transition.
- A press release announcing the leadership change was issued on December 18, 2025, and furnished as Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069899/000110465925122556/0001104659-25-122556-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069899/000110465925122556/tm2533792d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122556

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer